Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1954 1
1955 1
1956 2
1997 1
1998 2
2002 1
2003 1
2006 1
2012 1
2013 3
2018 1
2019 1
2020 1
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
Lesokhin A, LeBlanc R, Dimopoulos MA, Capra M, Carlo-Stella C, Karlin L, Castilloux JF, Forsberg P, Parmar G, Tosikyan A, Pour L, Ribrag V, Ribolla R, Abdallah AO, Le Roux N, Dong L, van de Velde H, Mayrargue L, Lépine L, Macé S, Moreau P. Lesokhin A, et al. Among authors: lepine l. Cancer Med. 2023 May;12(9):10254-10266. doi: 10.1002/cam4.5753. Epub 2023 Mar 3. Cancer Med. 2023. PMID: 36866838 Free PMC article. Clinical Trial.
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant.
Vincenti F, Bestard O, Brar A, Cruzado JM, Seron D, Gaber AO, Ali N, Tambur AR, Lee H, Abbadessa G, Paul JA, Dudek M, Siegel RJ, Torija A, Semiond D, Lépine L, Ternes N, Montgomery RA, Stegall M. Vincenti F, et al. Among authors: lepine l. J Am Soc Nephrol. 2024 Mar 1;35(3):347-360. doi: 10.1681/ASN.0000000000000287. Epub 2023 Dec 26. J Am Soc Nephrol. 2024. PMID: 38147137 Clinical Trial.
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
Carlo-Stella C, Zinzani PL, Sureda A, Araújo L, Casasnovas O, Carpio C, Yeh SP, Bouabdallah K, Cartron G, Kim WS, Cordoba R, Koh Y, Re A, Alves D, Chamuleau M, Le Gouill S, López-Guillermo A, Moreira I, van der Poel MWM, Abbadessa G, Meng R, Ji R, Lépine L, Saleem R, Ribrag V. Carlo-Stella C, et al. Among authors: lepine l. Hematol Oncol. 2023 Feb;41(1):108-119. doi: 10.1002/hon.3089. Epub 2022 Oct 31. Hematol Oncol. 2023. PMID: 36251503 Free PMC article. Clinical Trial.
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
Zucali PA, Lin CC, Carthon BC, Bauer TM, Tucci M, Italiano A, Iacovelli R, Su WC, Massard C, Saleh M, Daniele G, Greystoke A, Gutierrez M, Pant S, Shen YC, Perrino M, Meng R, Abbadessa G, Lee H, Dong Y, Chiron M, Wang R, Loumagne L, Lépine L, de Bono J. Zucali PA, et al. Among authors: lepine l. J Immunother Cancer. 2022 Jan;10(1):e003697. doi: 10.1136/jitc-2021-003697. J Immunother Cancer. 2022. PMID: 35058326 Free PMC article. Clinical Trial.
Hysterectomy surveillance--United States, 1980-1993.
Lepine LA, Hillis SD, Marchbanks PA, Koonin LM, Morrow B, Kieke BA, Wilcox LS. Lepine LA, et al. MMWR CDC Surveill Summ. 1997 Aug 8;46(4):1-15. MMWR CDC Surveill Summ. 1997. PMID: 9259214 Free article.
Supporting and Incentivizing Peer Leaders for an Internet-Based Private Peer Community for Youths With Type 1 Diabetes: Social Network and Directed Content Analysis.
Wu N, Wang SJ, Brazeau AS, Chan D, Mussa J, Nakhla M, Elkeraby M, Ell M, Prevost M, Lepine L, Panagiotopoulos C, Mukerji G, Butalia S, Henderson M, Da Costa D, Rahme E, Dasgupta K. Wu N, et al. Among authors: lepine l. J Med Internet Res. 2023 Dec 12;25:e48267. doi: 10.2196/48267. J Med Internet Res. 2023. PMID: 38085568 Free PMC article.
[Prevention of malocclusions].
LEPINE L. LEPINE L. J Can Dent Assoc (Tor). 1948 Jan;13(14):49; passim. J Can Dent Assoc (Tor). 1948. PMID: 18901235 French. No abstract available.
A factor analysis of some handwriting characteristics.
LORR M, LEPINE LT, GOLDER JV. LORR M, et al. Among authors: lepine lt. J Pers. 1954 Mar;22(3):348-53. doi: 10.1111/j.1467-6494.1954.tb01137.x. J Pers. 1954. PMID: 13143465 No abstract available.
22 results